Capricor Therapeutics investors who bought stock between December 17, 2025 and July 26, 2026 are the subject of a federal securities class action, and the deadline to ask the court to be named lead plaintiff was September 28, 2026. Glancy Prongay Wolke & Rotter LLP and Kessler Topaz Meltzer & Check have both publicized the case.
Capricor is a biotechnology company developing cell and exosome-based therapies for a rare genetic disorder that causes progressive muscle degeneration. Its lead candidate is Deramiocel, a cell therapy aimed at the cardiac and skeletal muscle complications of Duchenne muscular dystrophy.
What the complaint alleges
The suit says Capricor and its executives made materially false or misleading statements during the class period. According to the complaint, they did not tell investors that the company had changed the pre-specified statistical analysis plan used on the Deramiocel clinical data. Nor did they say the FDA had not agreed to those changes when Capricor resubmitted its Biologics License Application.
That gap, the complaint says, created a significant risk that the FDA would find the results did not show substantial evidence the drug works, putting approval for Duchenne at substantial risk. The company’s positive statements about its business and prospects were therefore misleading or lacked a reasonable basis, the suit contends.
Where the case stands
Kessler Topaz says motions to appoint a lead plaintiff and lead counsel were filed on September 28, 2026, and are still being briefed. The action is ongoing.
Glancy’s notice says investors may pick their own counsel or do nothing and stay on as absent class members. No class has been certified. The firm also notes that “prior results do not guarantee a similar outcome.”
Sources
- Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Class Action | Kessler Topaz





